Skip to main content
Caplight Logo









Point6 Bio

Point6 Bio

Private
Tel AvivHealthcare & Life Scienceshttps://point6.bio/

Last Round

Seed

May 1, 2023

Total Funding Raised

$1.4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Point6 Bio is a biotechnology company that develops an AI-driven computational biology platform for the early diagnosis and treatment of neurodevelopmental and neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

computational biologybiomarker discoverymulti-omicsprecision medicineproteomicspost-translational modificationPTMmedical AIdrug discoverypatient stratificationdiagnostic platformAI diagnosticsneurodegenerative diseaseneurodevelopmental disordersbiotechdigital biomarkers

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Point6 Bio Comparables

Compare Point6 Bio with similar companies based on industry and business-model similarity.

Point6 Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
iDiagnostix Ltd
84%
Andia Health
83%
Cell-El Therapeutics Ltd.
83%

Point6 Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 1, 2023
GrantMar 21, 2023

Key People

Founding team and executive leadership

Neta Barashi

Co-Founder & CEO

Founding Team

Point6 Bio Investors

Notable investors and investment history

Point6 Bio investors
InvestorRounds
VLX VenturesSeed
Endless Frontier LabsSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors grew 104% MoM.

  • Jun 6, 2024

    Grew 43% QoQ, from 7 to 10 employees.

Point6 Bio Filings

Explore SEC and related filing metadata, where available.

Point6 Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Point6 Bio's valuation, stock price, and market status.

Is Point6 Bio a public or private company?

Point6 Bio is a private company.

What is the current stock price of Point6 Bio?

Point6 Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Point6 Bio worth (valuation)?

Valuation information for Point6 Bio is not publicly available.

Can I buy Point6 Bio stock?

Point6 Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Point6 Bio's last funding round?

Point6 Bio's most recent funding round was Seed on May 1, 2023.

Who are the main investors in Point6 Bio?

Key investors in Point6 Bio include VLX Ventures, Endless Frontier Labs.

Will Point6 Bio IPO soon?

No public IPO plans have been announced for Point6 Bio.

How can I track Point6 Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Point6 Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersTel Aviv
Employee Range5
Year Founded2023
Last FundingMay 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?